Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dare Bioscience (DARE) EPS (Weighted Average and Diluted) (2016 - 2025)

Dare Bioscience (DARE) has disclosed EPS (Weighted Average and Diluted) for 8 consecutive years, with -$0.28 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 49.09% year-over-year to -$0.28, compared with a TTM value of -$1.88 through Sep 2025, up 49.19%, and an annual FY2024 reading of -$0.48, up 88.43% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.28 for Q3 2025 at Dare Bioscience, up from -$0.45 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.52 in Q2 2024 and bottomed at -$3.86 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.47, with a median of -$0.19 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 26981.88% in 2023, then surged 224.59% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.11 in 2021, then tumbled by 72.73% to -$0.19 in 2022, then tumbled by 1931.58% to -$3.86 in 2023, then skyrocketed by 83.16% to -$0.65 in 2024, then skyrocketed by 56.92% to -$0.28 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for DARE at -$0.28 in Q3 2025, -$0.45 in Q2 2025, and -$0.5 in Q1 2025.